Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences

• The most recent release (April 27, 2026) details a presentation of first-in-human clinical data from Targeted Hyperthermia Therapy (THT) at the American Association for Cancer Research (AACR) conference.
• Key findings reiterate previous announcements: 6 out of 10 late-stage melanoma patients achieved complete response in treated tumors after failing standard immunotherapy.
• The therapy utilizes proprietary gold nanorods to deliver precise heat (42-48°C) to stimulate the immune system.
• Safety and tolerability were highlighted as positive attributes in this cohort.
• A manuscript is being prepared for peer-reviewed submission, and data will be presented at ASCO from May 29 – June 2, 2026.
• This news follows a sequence of updates starting October 2025 (initial clinical results) and April 13, 2026 (tissue analysis confirming immunotherapy synergy).

• The core efficacy data presented at AACR was previously disclosed in the October 20, 2025 release ("80% Response Rate... 6/8 complete histologic remission").
• As this news confirms existing public information rather than introducing new patient cohorts or superior efficacy metrics, it does not meet the threshold for "Material - Positive" regarding new value creation.
• The stock price has declined significantly from its July 2025 peak ($0.79) to current levels (~$0.31), suggesting the market may have already priced in the initial clinical optimism or is concerned about capital needs not detailed in these releases.
• The announcement serves as a validation of the October data and sets up the ASCO presentation (May-June 2026) as the next potential catalyst, but immediate material upside is limited by the lack of new quantitative data.
• Classification: Routine - Positive due to incremental confirmation and upcoming catalyst visibility without fundamental change in risk profile or valuation drivers.

• Company: Sona Nanotech Inc. operates in the biotechnology sector focusing on nanotechnology-based cancer therapies.
• Flagship Project: Targeted Hyperthermia Therapy (THT). This utilizes gold nanorods to absorb infrared light, delivering heat to tumors to stimulate an immune response and shrink them.
• Development Stage: Early feasibility clinical trials completed in melanoma patients; preclinical studies show synergy with immunotherapy in colorectal cancer models.
• Management: Dr. Carman Giacomantonio serves as Chief Medical Officer. David Regan is CEO. Dr. Len Pagliaro transitioned to a board-only role in October 2025.